Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Oaktree Acquisition Corp. III Life SciencesOACC · Entity 6078 | Director | October 23, 2024 | October 24, 2024 |
| ZEVRA THERAPEUTICS, INC.ZVRA · Entity 5212 | Director | June 04, 2026 | June 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Oaktree Acquisition Corp. III Life Sciences
Report date October 23, 2024 · Filed October 24, 2024
This filing explicitly reported no securities owned.
ZEVRA THERAPEUTICS, INC.
Report date June 04, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.17 · Expires 2036-06-03 | Direct | 30,000 |
Reported balance
After 2026-06-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 30,000 · Balance 30,000 F1: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, June 4, 2026. F2: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's tenth amended and restated non-employee director compensation policy. F3: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) the date that is one day prior to the first annual stockholders meeting occurring after the grant date or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, June 4, 2026.
F2: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's tenth amended and restated non-employee director compensation policy.
F3: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) the date that is one day prior to the first annual stockholders meeting occurring after the grant date or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 04, 2026 Filed Jun 18, 2026 20:15 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $11.17 | $0.00 |
DisclosureSEC source: 0001434647-26-000050 · wk-form4_1781813721.xml · derivative · entry 1 Shih Alvin · CIK 0001610064 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2036-06-03 F1 · derivative.exercise_price: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, June 4, 2026. F2 · shares: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's tenth amended and restated non-employee director compensation policy. F3 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) the date that is one day prior to the first annual stockholders meeting occurring after the grant date or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date. Read SEC document |
| September 12, 2025 Filed Sep 15, 2025 20:07 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | PurchaseCommon Stock | 20,000 | $7.89 | $157,800.00 |
DisclosureSEC source: 0001610064-25-000011 · wk-form4_1757966847.xml · nonDerivative · entry 1 Shih Alvin · CIK 0001610064 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.85 to $7.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| May 29, 2025 Filed May 31, 2025 01:41 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $8.62 | $0.00 |
DisclosureSEC source: 0001437749-25-019050 · rdgdoc.xml · derivative · entry 1 Shih Alvin · CIK 0001610064 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2035-05-28 F1 · derivative.exercise_price: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, May 29, 2025. F2 · shares: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's tenth amended and restated non-employee director compensation policy. F3 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) the date that is one day prior to the first annual stockholders meeting occurring after the grant date or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date. Read SEC document |
| May 13, 2024 Filed May 16, 2024 01:13 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | GrantStock Option (right to buy) · Derivative | 39,200 | $0.00 Strike: $4.89 | $0.00 |
DisclosureSEC source: 0001437749-24-017179 · rdgdoc.xml · derivative · entry 1 Shih Alvin · CIK 0001610064 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,200 Underlying: Common Stock · 39,200 shares Expires 2034-05-12 F1 · derivative.exercise_price: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, May 13, 2024. F2 · shares: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's ninth amended and restated non-employee director compensation policy. F3 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) one day prior to the date of the first annual meeting of the Issuer's stockholders following the date of grant or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date. Read SEC document |
| January 20, 2024 Filed Feb 3, 2024 01:08 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | GrantStock Option (right to buy) · Derivative | 58,800 | $0.00 Strike: $5.72 | $0.00 |
DisclosureSEC source: 0001437749-24-003020 · rdgdoc.xml · derivative · entry 1 Shih Alvin · CIK 0001610064 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,800 Underlying: Common Stock · 58,800 shares Expires 2034-01-19 F1 · derivative.exercise_price: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, January 19, 2024. F2 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's 2014 Equity Incentive Plan (the "Plan"). 33.33% of the shares will vest on January 20, 2025 and the remaining 66.67% of the shares will vest in equal annual installments thereafter, provided that at the relevant vesting dates such optionee's employment relationship has not been terminated as defined in the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason. The option expires ten years after the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.